symproic
symproic: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI) | Approved |
FDA Decisions
Frequently asked questions
Who is developing symproic?
symproic is being developed by BIODELIVERY SCIENCES INTERNATIONAL INC.
What is symproic's latest FDA decision?
The most recent tracked FDA decision for symproic is Approval for 1 INDICATIONS AND USAGE SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. SYMPROIC is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior canc, dated March 23, 2017.
Get deeper analysis on symproic
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis